Новые диагностические возможности определения активности язвенного колита: роль нейтрофилов
https://doi.org/10.20514/2226-6704-2022-12-4-285-292
Аннотация
Заболеваемость язвенным колитом в последние годы растет, и его развитие в молодом возрасте стало тенденцией, которая прогностически неблагоприятна. Клиническая картина язвенного колита часто расплывчата, что приводит к изначально ошибочному диагнозу. Оценка эффективности лечения и риска рецидива язвенного колита, требующая инвазивного вмешательства — одна из основных диагностических проблем. Целью исследования был анализ данных современной научной литературы о неинвазивных биомаркерах язвенного колита. Проанализированы данные зарубежных и отечественных статей по теме исследования, опубликованных в Pubmed и eLibrary за последние 5-10 лет. Биомаркеры нейтрофильного происхождения являются перспективным направлением в первичной диагностике и оценке активности язвенного колита.
Ключевые слова
Об авторах
Е. В. Болотова
ФГБОУ ВО КубГМУ Минздрава России
Россия
Россия
Краснодар
К. А. Юмукян
ФГБОУ ВО КубГМУ Минздрава России; Государственное бюджетное учреждение здравоохранения «Научно-исследовательский институт — Краевая клиническая
больница № 1 им. С.В. Очаповского»
Россия
Россия
Краснодар
А. В. Дудникова
ФГБОУ ВО КубГМУ Минздрава России
Россия
Россия
Краснодар
Список литературы
1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018; 390(10114): 2769−2778. doi: 10.1016/S0140-6736(17)32448-0
2. Маев И.В., Шелыгин Ю.А., Скалинская М.И., и др. Патоморфоз воспалительных заболеваний кишечника. Вестник Российской академии медицинских наук. 2020; 75(1): 27-35. doi:10.15690/vramn1219
3. Тертычный А.С., Ахриева Х.М., Маев И.В., др. Проблемы диагностики гистологической ремиссии у больных с воспалительными заболеваниями кишечника. Архив патологии. 2017; 79(3): 3-9. doi:10.17116/patol20177933-9
4. Tang L, Xu M. Candidate polymorphisms and susceptibility to inflammatory bowel disease: A systematic review and meta-analysis. Gene. 2020; 30; 753: 144814. doi: 10.1016/j.gene.2020.144814
5. Wu PB, Qian R, Hong C, et al. Association between PTGER4 polymorphisms and inflammatory bowel disease risk in Caucasian: A meta-analysis. Medicine (Baltimore). 2020; 99(34): e19756. doi: 10.1097/MD.0000000000019756.
6. Zhao M, Feng R, Ben-Horin S, et al. Systematic review with metaanalysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations. Aliment Pharmacol Ther. 2022; 55(3): 266-276. doi: 10.1111/apt.16703
7. Zhong Y, Zhang Z, Lin Y, Wu L. The Relationship Between Helicobacter pylori and Inflammatory Bowel Disease. Arch Iran Med. 2021; 1; 24(4): 317-325. doi: 10.34172/aim.2021.44
8. Lambert K, Pappas D, Miglioretto C et al. Systematic review with meta-analysis: dietary intake in adults with inflammatory bowel disease. Aliment Pharmacol Ther. 2021; 54(6): 742-754. doi: 10.1111/apt.16549
9. Халиф И.Л., Шапина М.В., Головенко А.О., и др. Течение хронических воспалительных заболеваний кишечника и методы их лечения, применяемые в Российской Федерации (результаты многоцентрового популяционного одномоментного наблюдательного исследования). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018; 28(3): 54−62. doi:10.22416/1382-4376-2018-28-3-54-62
10. Rath T, Atreya R, Neurath MF. Is histological healing a feasible endpoint in ulcerative colitis? Expert Rev Gastroenterol Hepatol. 2021; 15(6): 665-674. doi: 10.1080/17474124.2021.1880892
11. Solitano V, D’Amico F, Allocca M., et al. Rediscovering histology: what is new in endoscopy for inflammatory bowel disease? Therap Adv Gastroenterol. 2021; 14: 17562848211005692. doi: 10.1177/17562848211005692
12. Arkteg CB, Wergeland Sørbye S, Buhl Riis L, et al. Real-life evaluation of histologic scores for Ulcerative Colitis in remission. PLoS One. 2021; 16(3): e0248224. doi: 10.1371/journal.pone.0248224
13. Shah J, Dutta U, Das A, et al. Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: A prospective study. JGH Open. 2019; 4(3): 382-386. doi: 10.1002/jgh3.12260
14. Muthas D, Reznichenko A, Balendran CA, et al. Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. Scand J Gastroenterol. 2017; 52(2): 125-135. doi: 10.1080/00365521.2016.1235224.
15. Singh UP, Singh NP, Murphy EA, et al. Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine. 2016; 77: 44-49. doi:10.1016/j.cyto.2015.10.008
16. Arkteg CB, Wergeland Sørbye S, Buhl Riis L, et al.Real-life evaluation of histologic scores for Ulcerative Colitis in remission. PLoS One. 2021; 16(3): e0248224. doi:10.1371/journal.pone.0248224
17. Ayling RM, Kok K. Fecal Calprotectin. Adv Clin Chem. 2018; 87: 161- 190. doi: 10.1016/bs.acc.2018.07.005
18. Drury B, Hardisty G, Gray RD, Ho GT. Neutrophil Extracellular Traps in Inflammatory Bowel Disease: Pathogenic Mechanisms and Clinical Translation. Cell Mol Gastroenterol Hepatol. 2021; 12(1): 321-333. doi: 10.1016/j.jcmgh.2021.03.002
19. Fu Y, Wang L, Xie C, et al. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation. Sci Rep. 2017; 7(1): 2669. doi: 10.1038/s41598-017-02835-5
20. Nemakayala DR, Cash BD. Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go? Curr Opin Gastroenterol. 2019; 35(1): 58-62. doi: 10.1097/MOG.0000000000000493
21. Magro F, Lopes S, Coelho R et al. Portuguese IBD Study Group [GEDII]. Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis-the ACERTIVE study. J Crohns Colitis. 2017; 11(4): 435-444. doi: 10.1093/ecco-jcc/jjw170
22. Hart L, Chavannes M, Kherad O, et al. Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis. J Crohns Colitis. 2020; 14(1): 46-52. doi: 10.1093/ecco-jcc/jjz107
23. MH, Zou G, Garg SK, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015; 110(6): 802-19; quiz 820. doi: 10.1038/ajg.2015.120
24. Frin AC, Filippi J, Boschetti G, et al. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis. Dig Liver Dis. 2017; 49(1): 11-16. doi: 10.1016/j.dld.2016.09.001
25. Sakuraba A, Nemoto N, Hibi N, et al. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis. BMC Gastroenterol. 2021; 21(1): 197. doi: 10.1186/s12876-021-01788-4
26. Grabherr F, Effenberger M, Pedrini A, et al. Increased Fecal Neopterin Parallels Gastrointestinal Symptoms in COVID-19. Clin Transl Gastroenterol. 2021; 12(1): e00293. doi: 10.14309/ctg.0000000000000293
27. Jangi S, Holmer AK, Dulai PS, et al. Risk of Relapse in Patients With Ulcerative Colitis With Persistent Endoscopic Healing: A Durable Trea tment Endpoint.J Crohns Colitis. 2021; 15(4): 567-574. doi: 10.1093/ecco-jcc/jjaa184
28. Langhorst J, Boone J, Lauche R, et al. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial, Journal of Crohn’s and Colitis. 2016; 10(7): 786–794. doi: 10.1093/ecco-jcc/jjw044
29. Rubio MG, Amo-Mensah K, Gray JM, et al. Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2019; 10(5): 54-63. doi: 10.4291/wjgp. v10.i5.54
30. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010; 59(9): 1207-12. doi: 10.1136/gut.2010.211755
31. Faubion WA Jr, Fletcher JG, O’Byrne S, et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn’s disease activity: role of crosssectional imaging. Am J Gastroenterol. 2018; 108(12): 1891-900. doi: 10.1038/ajg.2013.354
32. Wang Y, Pei F, Wang X, et al. Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis. Int J Clin Exp Pathol. 2015; 8(10): 12319-32
33. Osterman MT, Aberra FN, Cross R, et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clinical Gastroenterology and Hepatology. 2014; 12(11): 1887,1893 e3.
34. Molander P, Sipponen T, Kemppainen H, et al. Achievement of deep remission during scheduled maintenance therapy with TNFa-blocking agents in IBD. J Crohn’s Colitis. 2013; 7(9): 730-5. doi:10.1016/j. crohns.2012.10.018
35. Нестерова И.В, Колесникова Н.В., Чудилова Г.А., и др. Нейтрофильные гранулоциты: новый взгляд на «старых игроков» на иммунологическом поле. Иммунология. 2015; 4: 257-263
36. O’Sullivan S, Gilmer JF, Medina C. Matrix metalloproteinases in inflammatory bowel disease: an update. Mediators Inflamm. 2015; 2015: 964131. doi: 10.1155/2015/964131
37. Sandborn WJ, Bhandari BR, Fogel R, et al. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther. 2016; 44(2): 157-69
38. Thorsvik S, Damås JK, Granlund AV, et al. Fecal neutrophil gelatinaseassociated lipocalin as a biomarker for inflammatory bowel disease. J Gastroenterol Hepatol. 2017; 32(1): 128-135. doi: 10.1111/jgh.13598
39. de Bruyn M, Arijs I, De Hertogh G, et al. Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn’s Disease. J Crohns Colitis. 2015; 9(12): 1079-87. doi: 10.1093/eccojcc/jjv148
40. Wang J, Ortiz C, Fontenot L, et al. High circulating elafin levels are associated with Crohn’s disease-associated intestinal strictures. PLoS One. 2020; 15(4): e0231796. doi: 10.1371/journal.pone.0231796
41. Zhang W, Teng G, Wu T, et al.Expression and Clinical Significance of Elafin in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017; 23(12): 2134-2141. doi: 10.1097/MIB.0000000000001252
42. Barry R, Ruano-Gallego D, Radhakrishnan ST, et al. Faecal neutrophil elastase-antiprotease balance reflects colitis severity. Mucosal Immunol. 2020;13(2):322-333. doi: 10.1038/s41385-019-0235-4
43. Jakimiuk K, Gesek J, Atanasov AG, et al. Flavonoids as inhibitors of human neutrophil elastase. J Enzyme Inhib Med Chem. 2021; 36(1): 1016-1028. doi: 10.1080/14756366.2021.1927006
44. Curciarello R, Sobande T, Jones S, et al. Neutrophil Elastase Proteolytic Activity in Ulcerative Colitis Favors the Loss of Function of Therapeutic Monoclonal Antibodies. J Inflamm Res. 2020; 13: 233-243. doi: 10.2147/JIR.S234710
45. Mizuochi T, Arai K, Kudo T, et al. Diagnostic accuracy of serum proteinase 3 antineutrophil cytoplasmic antibodies in children with ulcerative colitis. J Gastroenterol Hepatol. 2021; 36(6): 1538-1544. doi: 10.1111/jgh.15296.
46. Xu Y, Xu F, Li W, et al. The diagnostic role and clinical association of serum proteinase 3 anti-neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease. Scand J Gastroenterol. 2020; 55(7): 806-813. doi: 10.1080/00365521. 2020.178192
47. De Bruyn M, Ceuleers H, Hanning N, et al. Proteolytic Cleavage of Bioactive Peptides and Protease-Activated Receptors in Acute and Post-Colitis. Int J Mol Sci. 2021; 22(19): 10711. doi: 10.3390/ijms221910711
48. Malech HL, DeLeo FR, Quinn MT. The Role of Neutrophils in the Immune System: An Overview. Methods Mol Biol. 2020; 2087: 3-10. doi: 10.1007/978-1-0716-0154-9_1
49. Fujita M, Kawabata H, Oka T, et al. Rare Case of Adult Autoimmune Neutropenia Successfully Treated with Prednisolone. Intern Med. 2017; 56(11): 1415-1419. doi: 10.2169/internalmedicine.56.7619
50. Planell N, Masamunt MC, Leal RF, et al. Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis. J Crohns Colitis. 2017; 11(11): 1335-1346. doi: 10.1093/ecco-jcc/jjx09
Рецензия
Для цитирования:
Болотова Е.В., Юмукян К.А., Дудникова А.В. Новые диагностические возможности определения активности язвенного колита: роль нейтрофилов. Архивъ внутренней медицины. 2022;12(4):285-292. https://doi.org/10.20514/2226-6704-2022-12-4-285-292
For citation:
Bolotova E.V., Yumukyan K.A., Dudnikova A.V. New Diagnostic Possibilities for Determining the Activity of Ulcerative Colitis: The Role of Neutrophils. The Russian Archives of Internal Medicine. 2022;12(4):285-292. https://doi.org/10.20514/2226-6704-2022-12-4-285-292
Просмотров:
380
Послать статью по эл. почте 